Mesoblast (ASX:MSB) secured a regenerative advanced therapy designation from the US Food and Drug Administration for Revascor-branded rexlemestrocel-L cell therapy for pediatric patients with congenital heart disease, according to a Thursday filing with the Australian bourse.
The status was granted following results from a clinical trial investigating the use of the therapy in children with hypoplastic left heart syndrome (HLHS), the filing said.
Revascor was previously granted by the health regulator with both a rare pediatric disease designation and an orphan drug designation for pediatric patients with HLHS, the filing added.
The company's shares tumbled almost 8% in recent Thursday trade but earlier hit their highest since August 2021.
Price (AUD): $1.62, Change: $-0.14, Percent Change: -7.95%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.